List | Section | Observation |
---|---|---|
Peru | 10.2 Medications that Affect Coagulation | No observations |
List | Section | Observation |
---|---|---|
Peru | 10.2 Medications that Affect Coagulation | No observations |
List | Section | Observation |
---|---|---|
Venezuela (incomplete) | List of Generic Medications - Venezuela | No observations |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 10.2. Medicines affecting coagulation |
Others observations: Including quality-assured biosimilars. Therapeutic alternatives: dalteparin, nadroparin |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 10.2. Medicines affecting coagulation |
Others observations: Including quality-assured biosimilars. Therapeutic alternatives: dalteparin, nadroparin |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 10.2. Medicines affecting coagulation |
Others observations: Including quality-assured biosimilars. Therapeutic alternatives: dalteparin, nadroparin |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 10.2. Medicines affecting coagulation |
Others observations: Including quality-assured biosimilars. Therapeutic alternatives: dalteparin, nadroparin |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 10.2. Medicines affecting coagulation |
Others observations: Including quality-assured biosimilars. Therapeutic alternatives: dalteparin, nadroparin |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 10.2. Medicines affecting coagulation |
Others observations: Including quality-assured biosimilars. Therapeutic alternatives: dalteparin, nadroparin |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 10.2. Medicines affecting coagulation |
Others observations: Including quality-assured biosimilars. Therapeutic alternatives: dalteparin, nadroparin |